Exactis’ state of the art database provides remarkable opportunities using real world date; to study natural history of particular patient sub-groups or to provide ghost controls that are matched to experimental drug treated patients, or to help transform patient support or special access programs into data to support accelerated approval of new and effective drugs. This paper demonstrates that Exactis can use this DB to generate Canada wide data, and that it can be augmented by additional data retrieval.
🎉 Exciting News! 🎉 Our latest scientific article titled "Third-Line Treatment Patterns in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis of Real-World Data in Canada" in collaboration with Knight Therapeutics has just been published in the Journal of Pharmacy & Pharmaceutical Sciences!
Our study reveals a lack of consensus in Canada for post-second-line treatment of HER2+ metastatic breast cancer, highlighting significant delays in accessing new treatments in this indication. This underscores the need for a modernized system for faster drug access and reimbursement in Canada.
Read more below and leave us a comment to discuss how we can improve treatment access for cancer patients in Canada.
#breastcancer #publication #RWE #RealWorldEvidence #cancerresearch
Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada
frontierspartnerships.org
Felix Perez, CEO Research Director
2moHuge congratulations on receiving the FDA Breakthrough Therapy Designation! This milestone underscores the potential of your ADC to make a significant impact on the lives of patients with metastatic breast cancer. Exciting progress for the Daiichi Sankyo oncology pipeline! #BreastCancer #Oncology #BreakthroughTherapy